Considering the prevalence of eALT in our sample of employees (18.5%) in the context of the existing body of literature has to be done with caution since studies may vary widely according to thresholds for elevated ALT, distribution of risk factors within the population studied and diagnosis of NAFLD (e.g. via imaging procedures, liver enzymes or biopsy). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.